Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.50 |
| ▸ | MELK | Q14680 | 9/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.48 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.48 |
| ▸ | NUAK1 | O60285 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.48 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.48 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.48 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.43 |
| ▸ | KDR | P35968 | 7/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 2/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851519 | 1.00 | AAK1 (0.50) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| SCHEMBL30577752 | 1.00 | AAK1 (0.50) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| SCHEMBL30577753 | 1.00 | AAK1 (0.50) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| Acetic Acid SCHEMBL19283596 | 0.98 | AAK1 (0.49) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| SCHEMBL19283556 | 0.97 | AAK1 (0.48) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| Phosphoric Acid SCHEMBL19283570 | 0.97 | AAK1 (0.48) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| Maleic Acid SCHEMBL19283594 | 0.96 | AAK1 (0.47) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| SCHEMBL18825322 | 0.95 | AAK1 (0.47) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| SCHEMBL19283636 | 0.95 | AAK1 (0.47) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| Water SCHEMBL30195876 | 0.95 | AAK1 (0.46) | AAK1MELKCHEK1PRKAB2NUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643309-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2020-04-29 | — | — | EP | claimed |
| EP-2786765-B1 | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-10-03 | — | — | EP | claimed |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | claimed |
| EP-2878297-A1 | Medicaments for the treatment or prevention of fibrotic diseases | Boehringer Ingelheim International GmbH (DE) | 2015-06-03 | — | — | EP | claimed |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | US | claimed |
| WO-2012052757-A1 | TUMOUR PHENOTYPE PATIENT SELECTION METHOD | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | WO | claimed |
| EP-1527047-B1 | 3-Z- 1-(4-(N-((4-METHYL-PIPERAZIN-1-YL)-METHYLCARBONYL)-N-ME THYL-AMINO)-ANILINO)-1-PHENYL-METHYLENE -6-METHOXYCARBONYL-2 -INDOLINONE-MONOETHANESULPHONATE AND THE USE THEREOF AS A PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-03-28 | — | — | EP | claimed |
| EP-2384751-A1 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-09 | — | — | EP | claimed |
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | claimed |
| JP-2008525370-A | — | — | 2008-07-17 | — | — | JP | claimed |
| EP-1830843-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-09-12 | — | — | EP | claimed |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| WO-2006067165-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | WO | claimed |
| US-20250136580-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-01 | — | — | US | disclosed |
| US-20240165078-A1 | THERAPEUTIC TARGETING OF RECEPTOR TYROSINE KINASE INHIBITOR-INDUCED ANDROGEN RECEPTOR PHOSPHORYLATION IN CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2024-05-23 | — | — | US | disclosed |
| WO-2024094844-A1 | ORAL FORMULATION OF N-PYRIDINYL ACETAMIDE DERIVATIVE FOR TREATING INTERSTITIAL LUNG DISEASE | ASTRAZENECA AB (SE) | 2024-05-10 | — | — | WO | disclosed |
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-1830843-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| WO-2006067165-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | AAK1 3831/4885MELK 2222/4885CHEK1 4470/4885 |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | MMP1, COL1A1, FOXM1 | AAK1 3831/4885MELK 2222/4885CHEK1 4470/4885 |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | AAK1 3831/4885MELK 2222/4885CHEK1 4470/4885 |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | AAK1 3831/4885MELK 2222/4885CHEK1 4470/4885 |
| US-20250136580-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | MELK, HIPK1, HIPK3 | AAK1 65/4885MELK 1/4885CHEK1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.